From bench to clinic and back: Perspective on the 1stIQPC Translational Research conference

Journal of Translational Medicine

Volumn 2, Issue , 2004, Pages

  Hörig, Heidi ^a   Pullman, William ^b  

^a NewYork Presbyterian Hospital   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; DRUG;

AUTHORITY; CANCER; CANCER GENETICS; CARCINOGENESIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG BINDING; DRUG DISTRIBUTION; DRUG INDUSTRY; DRUG PENETRATION; DRUG RESEARCH; DRUG SCREENING; ECHOGRAPHY; GENE EXPRESSION; GENOMICS; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; HUMAN; INFORMATION PROCESSING; INTERPERSONAL COMMUNICATION; LANGUAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROTEIN MICROARRAY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TECHNOLOGY; UNITED STATES; UNIVERSITY;

EID: 18144396919     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-2-44     Document Type: Review

References (14)

1. Innovation stagnation: Challenge and Opportunity on the Critical Path to new medical products. US Department of Health and Human Services 2004.
2. Marincola FM: Translational medicine: a two way road. J Transl Med 2003, 1:1.
3. The Biomarker Definitions Working Group: Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
4. Boyle EI, Weng S, Gollub J, Jin H, Botstein D, Cherry JM, Sherlock G: GO: TermFinder - open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Bioinformatics 2004, 20:3710-3715.
5. Leung SY, Chen X, Chu KM, Yuen ST, Mathy J, Ji J, Chan AS, Li R, Law S, Troyanskaya OG, Tu IP, Wong J, So S, Botstein D, Brown PO: Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci U S A 2002, 10(99):16203-8.
6. Wang E, Adams S, Zhao Y, Panelli M, Simon R, Klein H, Marincola FM: A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings. J Transl Med 2003, 1:4.
7. Panelli MC, White R, Foster M, Martin B, Wang E, Smith K, Marincola FM: Forecasting the cytokine storm following systemic interleukin-2 administration. J Transl Med 2004, 2:17.
8. Monsurro' V, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K, Nagorsen D, Connors M, Jacobson S, Marincola FM: Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 2004, 104:1970-1978.
9. Vakkila J, Lotze MT: Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004, 4(8):641-8.
10. Lotze MT, DeMarco RA: Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs 2003, 4(12):1405-9.
11. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48:1296-304.
12. Petricoin EF, Liotta LA: SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004, 15(1):24-30.
13. Cowherd SM, Espina VA, Petricoin EF 3rd, Liotta LA: Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays. Clin Breast Cancer 2004, 5(5):385-92.
14. Lappin G, Garner RC: Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nature reviews, Drug Discovery 2003, 2:233-240.